UNIVO PHARMACEUTICALS LTD |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 93,000 ILa | 0.00% |
|
0.00% | 0.00% |
| Sales 2019 | 0.82 314.25 | Sales 2020 | 33.68 12.84K | Capitalization | 75.1M 28.64B |
|---|---|---|---|---|---|
| Net income 2019 | -11M -4.2B | Net income 2020 | - 0 | EV / Sales 2019 | 35,543,010 x |
| Net cash position 2019 | 22.82M 8.7B | Net Debt 2020 | 4.12M 1.57B | EV / Sales 2020 | 2,352,105 x |
| P/E ratio 2019 * |
-
| P/E ratio 2020 |
-
| Employees | 76 |
| Yield 2019 * |
-
| Yield 2020 |
-
| Free-Float | 59.28% |
More Fundamentals
* Assessed data
More press releases
3 years
90 000.00
1 000 000.00
5 years
90 000.001 000 000.00
10 years
90 000.001 000 000.00
| Managers | Title | Age | Since |
|---|---|---|---|
Golan Bitton
CEO | Chief Executive Officer | 47 | 93-04-03 |
Jonathan Eilat
IRC | Investor Relations Contact | - | - |
Noam Frakash
AUD | Comptroller/Controller/Auditor | 41 | 21-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Chaim Hurvitz
CHM | Chairman | 63 | 19-07-14 |
Golan Bitton
CEO | Chief Executive Officer | 47 | 93-04-03 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-25 | 93,000 | 0.00% | 0 |
| 24-04-24 | 93,000 | 0.00% | 0 |
| 24-04-21 | 93,000 | 0.00% | 0 |
| 24-04-18 | 93,000 | 0.00% | 0 |
| 24-04-17 | 93,000 | 0.00% | 0 |
Delayed Quote TEL AVIV STOCK EXCHANGE, April 25, 2024 at 07:24 am EDT
More quotes
D-Pharm Ltd. is an Israel-based drug-development company. The Company is focused on developing drugs for the treatment of central nervous system (CNS) conditions. Its area of interest is in developing medicine for degenerative and age-related disorders. The Companyâs product portfolio includes three clinical Phase II drug-candidates: THR-18 for thrombolysis, to restore blood flow to the brain, heart or lungs, which completed clinical Phase I and Phase II study in acute stroke patients receiving tPA; DP-VPA for the treatment of epilepsy, migraine and manic depression, which has completed a Phase II study in patients with complex partial epilepsy, and DP-b99, which contains calcium, zinc and copper ions and is used for the protection of cells under stress in acute pancreatitis. The Companyâs two technology platforms Membrane Activated Chelator and Regulated Activation of Prodrug use lipid moieties conjugated onto actives such as metal ion chelators or drugs for site specific activation.
| 1st Jan change | Capi. | |
|---|---|---|
| 0.00% | 747K | |
| +1.12% | 42.59B | |
| +6.77% | 40.65B | |
| +47.07% | 40.57B | |
| -11.96% | 26.77B | |
| +6.01% | 24.81B | |
| -24.92% | 18.17B | |
| -3.63% | 11.7B | |
| +27.16% | 12.05B | |
| +7.30% | 11.1B |
- Stock Market
- Equities
- UNVO-M Stock
